What is Gen9bio?
Based in San Jose, California, Gen9bio operates at the intersection of synthetic biology and molecular diagnostics. The company specializes in the design and synthesis of DNA primers, alongside the development of specialized biological reagents such as TK and DHH antibodies. By providing these critical tools, Gen9bio serves as a foundational partner for laboratories and research institutions focused on pharmaceutical development, clinical diagnostics, and advanced genetic analysis. Its market position is defined by its technical precision in DNA synthesis, which enables researchers to accelerate the pace of discovery in complex biological systems.
How much funding has Gen9bio raised?
Gen9bio has raised a total of $50.4M across 6 funding rounds:
Private Equity
$500K
Debt
$2M
Series B
$1.6M
Debt
$395K
Private Equity
$21M
Series C
$25M
Private Equity (2009): $500K, investors not publicly disclosed
Debt (2010): $2M, investors not publicly disclosed
Series B (2011): $1.6M supported by PBM Capital Group and Draper Fisher Jurvetson
Debt (2012): $395K featuring Draper Fisher Jurvetson and PBM Capital Group
Private Equity (2013): $21M backed by Agilent, PBM Capital Group, The Kraft Group, and Draper Fisher Jurvetson
Series C (2014): $25M, investors not publicly disclosed
Key Investors in Gen9bio
Draper Fisher Jurvetson
A prominent venture capital firm with a global footprint, focused on identifying and funding extraordinary entrepreneurs across diverse technology and life science sectors.
PBM Capital Group
An investment group with deep expertise in healthcare and consumer products, known for supporting companies that adhere to rigorous FDA and industry standards.
Agilent
A global leader in life sciences and diagnostics, providing advanced instrumentation and software solutions that empower laboratories to achieve accurate, high-impact research outcomes.
What's next for Gen9bio?
Looking ahead, Gen9bio is positioned to leverage its recent capital infusion to deepen its market penetration in the life sciences and diagnostics sectors. With a robust history of backing from industry-leading venture firms and strategic corporate partners, the company is well-equipped to scale its manufacturing infrastructure and expand its portfolio of high-affinity antibodies. The strategic focus will likely center on enhancing operational efficiencies and broadening the application of its DNA primer design technology to meet the evolving needs of global research markets. As the company moves beyond its current growth phase, the emphasis will remain on maintaining its competitive edge through innovation and strategic partnerships that bridge the gap between laboratory research and commercial-scale application.
See full Gen9bio company page
